NCT00117377已完成4 期
Effects of Pimecrolimus Cream 1% on the Molecular and Cellular Profile of Adult Male Patients With Atopic Dermatitis
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- Novartis
- 入组人数
- 70
- 试验地点
- 3
- 主要终点
- Determining whether pimecrolimus cream has an effect on the cellular and molecular profile of atopic dermatitis skin, which is cleared of lesions and is otherwise clinically normal.
研究概览
简要总结
The purpose of this study is to identify how pimecrolimus cream 1% modifies the molecular and cellular changes associated with the post-lesional phase of atopic dermatitis (AD). Healthy volunteers and patients with atopic dermatitis will be studied.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 20 Years 至 —（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Inclusion criteria for patients with atopic dermatitis:
- •Outpatient at screening
- •Adult male >20 years old
- •Diagnosis of AD fulfilling the Hannifin and Rajka criteria
- •Mild to moderate AD (Investigator Global Assessment [IGA] 2-3; localized eczema area and severity index [EASI] 1-8)
- •AD affecting both arms and/or legs >10cm2 per target area
- •Willing to undergo 4 mm serial punch biopsies
- •Patient history of AD for at least 3 years
- •Inclusion criteria for healthy volunteers:
- •Volunteers must be males >20 years of age
- •Volunteers must be in good health, as determined by past medical history, physical examination, and vital signs
排除标准
- •Exclusion criteria for patients with atopic dermatitis:
- •Concurrent diseases/conditions and history of other diseases/conditions
- •Are immunocompromised or have a history of malignant disease
- •Have a history of rheumatic fever, heart valve replacement, prosthetic joints or other prosthetic constituents
- •Have concurrent skin disease (e.g. acne) of such severity in the study area that it could interfere with the study evaluation
- •Have previously reported poor or no clinical response to topical tacrolimus ointment (Protopic®) or pimecrolimus cream (Elidel®)
- •Have active skin infections
- •Present with clinical conditions other than atopic dermatitis that can interfere with the study treatment
- •Present with severe medical condition(s) that, in the opinion of the investigator, prohibits participation in the study
- •Are maintained on emollients that contain supplementary ingredients such as urea, alpha or beta-hydroxy acids, fruit acids, vitamins A, D or E
- •Have received phototherapy (e.g. UVA, UVB) or systemic therapy (e.g. immunosuppressants, cytostatics) known or suspected to have an effect on AD within 4 weeks of Visit 1 (screening)
- •Have received systemic corticosteroids ([CS] e.g. oral, intravenous, intraarticular, rectal) within 4 weeks of Visit 1 (screening). Patients on a stable maintenance dose of inhaled or intranasal CS may participate
- •Were treated with topical therapy, including topical calcineurin inhibitors (e.g. corticosteroids, tar) known or suspected to have an effect on AD during the current acute episode
- •Were treated with antihistamines within 7 days of Visit 1
- •Known serious adverse reactions or hypersensitivity to anesthetics such as lidocaine or mepivacaine
- •Excluded investigational drugs/hypersensitivity
- •Have received investigational drugs within 8 weeks of the first application of study drug or planned use of other investigational drugs during participation in this study
- •Have known hypersensitivity to any ingredient of the pimecrolimus cream 1% or this class of study drug
- •Exclusion criteria for healthy volunteers:
- •Erythrodermic patients, patients with Netherton's syndrome
- •Personal or family history of atopy (asthma, allergic rhinitis, atopic dermatitis)
- •Clinically significant findings during the physical examination
- •Have a history of rheumatic fever, heart valve replacement, prosthetic joints or other prosthetic constituents e.g. lens implants or hip joints
- •Volunteers with known serious adverse reactions or hypersensitivity to anesthetics such as lidocaine or mepivacaine
- •Participation in any clinical trial within one month prior to current trial
- •History of immunocompromise
- •History of positive hepatitis B surface antigen (HBsAg) or hepatitis C test result
- •Use of corticosteroids within 4 weeks prior to baseline
- •Were treated with antihistamines within 7 days of Visit 1
- •Phototherapy within 4 weeks prior to baseline
- •Topical therapy within 5 weeks prior to the study
- •Treatment with nephrotoxic drugs within 2 weeks prior to baseline (aminoglycosides, amphotericin B, colchicine)
研究组 & 干预措施
1
Experimental
Pimecrolimus
干预措施: Pimecrolimus (Drug)
2
Placebo Comparator
Placebo control twice daily application
干预措施: Placebo (Drug)
结局指标
主要结局
Determining whether pimecrolimus cream has an effect on the cellular and molecular profile of atopic dermatitis skin, which is cleared of lesions and is otherwise clinically normal.
次要结局
- Identifying cellular and molecular changes in skin in an acute phase of atopic dermatitis
研究者
研究点 (3)
Loading locations...
相似试验
已完成
4 期
Assessment of Pruritus Improvement With Pimecrolimus Treatment on the Areas Affected by Mild-to-moderate AD, in Patients 2- to 11- Year-oldAtopic DermatitisNCT00510003Novartis Pharmaceuticals117
已完成
4 期
Efficacy and Safety of Pimecrolimus Cream 1% in Patients ≥ 3 Months of Age With Mild or Moderate Atopic DermatitisAtopic DermatitisNCT00150059Novartis
已完成
3 期
5-Year Safety Study of Pimecrolimus Cream 1% in Infants 3 - 12 Months of Age With Mild to Moderate Atopic DermatitisAtopic DermatitisNCT00120523MEDA Pharma GmbH & Co. KG2,418
已完成
4 期
Pimecrolimus Cream 1% (Elidel®) and Medicated Device Cream (EletoneTM) in the Treatment and Maintenance of Atopic Dermatitis.Atopic DermatitisNCT01177566Emer, Jason, M.D.20
尚未招募
3 期
Comparing the outcomes pimecrolimus and mometasone cream in treatment of childhood vitiligoIRCT20230307057646N1Esfahan University of Medical Sciences62